Israel's PolyPid Q4 EPS improves on lower R&D expenses

Reuters

Yesterday

Israel's PolyPid Q4 EPS improves on lower R&D expenses

Overview

Israel biopharmaceutical firm's Q4 net loss was $8.5 mln, with improved loss per share
R&D expenses decreased due to completion of SHIELD II Phase 3 trial
Company in advanced U.S. partnership talks for D-PLEX100, received positive FDA feedback

Outlook

PolyPid plans rolling NDA submission for D-PLEX₁₀₀ by end of Q1 2026
Company in advanced U.S. partnership talks for D-PLEX₁₀₀ commercialization
PolyPid expects cash reserves to fund operations into second half of 2026

Result Drivers

REGULATORY ADVANCEMENT - Positive FDA feedback supports rolling NDA review for D-PLEX100, with submission expected by Q1 2026
TECHNOLOGY EXPANSION - Introduction of Kynatrix technology expands drug delivery capabilities beyond original PLEX technology

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		-$0.41
Q4 Net Income		-$8.50 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 177.8% above its February 10 closing price of $4.68

Press Release: ID:nGNX60TbgP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610932012"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610932012\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610932012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610932012","market":"nz","top_or_hot":-1,"title":"Israel's PolyPid Q4 EPS improves on lower R&D expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Israel's PolyPid Q4 EPS improves on lower R&amp;D expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Israel biopharmaceutical firm's Q4 net loss was $8.5 mln, with improved loss per share</p></li><li><p>R&amp;D expenses decreased due to completion of SHIELD II Phase 3 trial</p></li><li><p>Company in advanced U.S. partnership talks for D-PLEX100, received positive FDA feedback</p></li></ul><p><span>Outlook</span></p><ul><li><p>PolyPid plans rolling NDA submission for D-PLEX₁₀₀ by end of Q1 2026</p></li><li><p>Company in advanced U.S. partnership talks for D-PLEX₁₀₀ commercialization</p></li><li><p>PolyPid expects cash reserves to fund operations into second half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REGULATORY ADVANCEMENT - Positive FDA feedback supports rolling NDA review for D-PLEX100, with submission expected by Q1 2026</p></li><li><p>TECHNOLOGY EXPANSION - Introduction of Kynatrix technology expands drug delivery capabilities beyond original PLEX technology</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$8.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 177.8% above its February 10 closing price of $4.68</p></li></ul><p>Press Release: <span>ID:nGNX60TbgP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Israel's PolyPid Q4 EPS improves on lower R&D expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsrael's PolyPid Q4 EPS improves on lower R&D expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Israel's PolyPid Q4 EPS improves on lower R&amp;D expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Israel biopharmaceutical firm's Q4 net loss was $8.5 mln, with improved loss per share</p></li><li><p>R&amp;D expenses decreased due to completion of SHIELD II Phase 3 trial</p></li><li><p>Company in advanced U.S. partnership talks for D-PLEX100, received positive FDA feedback</p></li></ul><p><span>Outlook</span></p><ul><li><p>PolyPid plans rolling NDA submission for D-PLEX₁₀₀ by end of Q1 2026</p></li><li><p>Company in advanced U.S. partnership talks for D-PLEX₁₀₀ commercialization</p></li><li><p>PolyPid expects cash reserves to fund operations into second half of 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REGULATORY ADVANCEMENT - Positive FDA feedback supports rolling NDA review for D-PLEX100, with submission expected by Q1 2026</p></li><li><p>TECHNOLOGY EXPANSION - Introduction of Kynatrix technology expands drug delivery capabilities beyond original PLEX technology</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.41</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$8.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 177.8% above its February 10 closing price of $4.68</p></li></ul><p>Press Release: <span>ID:nGNX60TbgP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYPD","symbol_name":"PolyPid Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL1N3Z70LR:1","article_id":"2610932012","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610932012","pubTimestamp":1770813539,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Israel's PolyPid Q4 EPS improves on lower R&D expensesOverviewIsrael biopharmaceutical firm's Q4 net loss was $8.5 mln, with improved loss per shareR&D expenses decreased due to completion of SHIELD I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYPD":"PolyPid Ltd.","BK4007":"制药"},"translate_title":"以色列PolyPid第四季度每股收益因研发费用降低而改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYPD":0.9},"content_text":"Israel's PolyPid Q4 EPS improves on lower R&D expenses OverviewIsrael biopharmaceutical firm's Q4 net loss was $8.5 mln, with improved loss per shareR&D expenses decreased due to completion of SHIELD II Phase 3 trialCompany in advanced U.S. partnership talks for D-PLEX100, received positive FDA feedbackOutlookPolyPid plans rolling NDA submission for D-PLEX₁₀₀ by end of Q1 2026Company in advanced U.S. partnership talks for D-PLEX₁₀₀ commercializationPolyPid expects cash reserves to fund operations into second half of 2026Result DriversREGULATORY ADVANCEMENT - Positive FDA feedback supports rolling NDA review for D-PLEX100, with submission expected by Q1 2026TECHNOLOGY EXPANSION - Introduction of Kynatrix technology expands drug delivery capabilities beyond original PLEX technologyKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS-$0.41Q4 Net Income-$8.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for PolyPid Ltd is $13.00, about 177.8% above its February 10 closing price of $4.68Press Release: ID:nGNX60TbgPFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}